With more than 30 oncology partners, Gilead lays out its 2030 vision of 20 new approvals - Endpoints News

Gilead has had a rocky history in oncology. A brief recount of the past few quarters: Trodelvy, the crown jewel of Gilead’s $21 billion Immunomedics deal, underwhelmed Wall Street last month after the company kept details on the drug’s treatment of HR+/HER2- …

Most Alzheimer’s drugs, including Biogen’s aducanumab (Aduhelm) and Eli Lilly’s donanemab, target amyloid plaques, misfolded protein clumps that build up in the brain, which are a hallmark of Alzheim… [+540 chars]

full article...